- Home
- FHN vs LEGN Comparison
FHN vs LEGN Comparison
Compare FHN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHN
- LEGN
- Stock Information
- Founded
- FHN 1864
- LEGN 2014
- Country
- FHN United States
- LEGN United States
- Employees
- FHN N/A
- LEGN N/A
- Industry
- FHN Major Banks
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- FHN Finance
- LEGN Health Care
- Exchange
- FHN Nasdaq
- LEGN Nasdaq
- Market Cap
- FHN 10.7B
- LEGN 5.4B
- IPO Year
- FHN N/A
- LEGN 2020
- Fundamental
- Price
- FHN $21.92
- LEGN $38.96
- Analyst Decision
- FHN Buy
- LEGN Strong Buy
- Analyst Count
- FHN 17
- LEGN 12
- Target Price
- FHN $23.09
- LEGN $73.91
- AVG Volume (30 Days)
- FHN 5.9M
- LEGN 1.6M
- Earning Date
- FHN 07-16-2025
- LEGN 08-08-2025
- Dividend Yield
- FHN 2.74%
- LEGN N/A
- EPS Growth
- FHN N/A
- LEGN N/A
- EPS
- FHN 1.44
- LEGN N/A
- Revenue
- FHN $3,043,000,000.00
- LEGN $728,303,000.00
- Revenue This Year
- FHN $11.18
- LEGN $65.49
- Revenue Next Year
- FHN $3.73
- LEGN $53.76
- P/E Ratio
- FHN $15.23
- LEGN N/A
- Revenue Growth
- FHN 3.43
- LEGN 112.46
- 52 Week Low
- FHN $14.34
- LEGN $27.34
- 52 Week High
- FHN $22.44
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- FHN 68.56
- LEGN 66.26
- Support Level
- FHN $21.67
- LEGN $34.64
- Resistance Level
- FHN $22.22
- LEGN $39.88
- Average True Range (ATR)
- FHN 0.39
- LEGN 1.46
- MACD
- FHN 0.09
- LEGN 0.37
- Stochastic Oscillator
- FHN 87.94
- LEGN 87.67
About FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.